Methodist Germantown Radiation Oncology Center Offers New Cancer-Fighting Technology

Published On 11/28/2011

Germantown, Tenn. – Patients at Methodist Germantown Radiation Oncology Center located at 1381 South Germantown Road can now get radiation treatments for cancer in less time. With the new Elekta Synergy and its volumetric modulated arc therapy (VMAT) and other upgrades patients can cut their radiation treatments from 20 minutes to less than half that time. This advanced technology allows doctors to treat a wide range of malignant and benign cancers that typically would be inoperable.  

“We are very pleased that our patients will receive the benefits of this advanced technology,” said Holger Gieschen, M.D., medical director, radiation oncology. “Not only does it make treatment more convenient for our patients by reducing the length of time, but it also allows us to provide much more precise and targeted  treatment for a number of cancers including cancers within the brain, head and neck, pancreas, liver, prostate, and lungs.” 

Elekta Synergy along with its upgrades is so accurate that larger doses of radiation can be delivered while at the same time avoiding healthy tissue. This powerful system uses a 3-D image guidance system which allows physicians to directly focus radiation to localized areas very quickly. Since every case is different, the upgraded Elekta Synergy’s sophisticated software enables doctors to customized individual treatment plans for each patient. 

“Having the ability to create an individualized treatment plan that conforms very tightly to the tumor so we affect healthy tissue less, means we can improve patient outcomes,” said Dr. Gieschen.  

This advanced digital linear accelerator allows radiation oncologists at the Methodist Germantown Radiation Oncology Center to obtain images just before treatment with the patient in the exact position he or she will be treated in. This means more accurate targeting for the radiation and patient positioning, but also the ability to increase the dose to the tumor by virtue of more certainty in the tumor’s location. The goal is to improve the patient’s quality of life and the chances of long-term survival.